Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $34.50 Average Price Target from Analysts

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) have earned a consensus recommendation of "Buy" from the six ratings firms that are covering the company, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $34.50.

A number of brokerages have recently commented on CAPR. Piper Sandler began coverage on shares of Capricor Therapeutics in a report on Monday, October 21st. They issued an "overweight" rating and a $35.00 target price on the stock. Maxim Group upped their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, September 25th. HC Wainwright restated a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald increased their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday, November 14th. Finally, Oppenheimer reiterated an "outperform" rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd.

Insider Activity at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the company's stock in a transaction that occurred on Friday, September 20th. The stock was purchased at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the purchase, the insider now directly owns 7,090,351 shares of the company's stock, valued at approximately $38,004,281.36. This trade represents a 65.21 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 12.00% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in Capricor Therapeutics in the 3rd quarter valued at about $458,000. Barclays PLC lifted its holdings in shares of Capricor Therapeutics by 106.6% in the third quarter. Barclays PLC now owns 36,296 shares of the biotechnology company's stock valued at $552,000 after purchasing an additional 18,724 shares in the last quarter. Sphera Funds Management LTD. purchased a new stake in shares of Capricor Therapeutics in the third quarter valued at about $938,000. State Street Corp grew its position in shares of Capricor Therapeutics by 27.8% in the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock valued at $7,792,000 after purchasing an additional 111,291 shares during the last quarter. Finally, Sassicaia Capital Advisers LLC purchased a new position in shares of Capricor Therapeutics during the 3rd quarter worth approximately $192,000. Hedge funds and other institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Stock Down 0.2 %

CAPR traded down $0.03 during trading on Friday, hitting $19.01. 571,850 shares of the stock were exchanged, compared to its average volume of 1,108,092. Capricor Therapeutics has a 1-year low of $2.90 and a 1-year high of $23.40. The stock has a fifty day moving average price of $18.03 and a two-hundred day moving average price of $9.44. The firm has a market capitalization of $864.38 million, a P/E ratio of -17.93 and a beta of 4.00.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.